RP1/Nivolumab Combo Shows Durable Responses, Favorable Safety in Melanoma

RP1 (vusolimogene oderparepvec) combined with nivolumab (Opdivo) showed durable antitumor activity and a favorable safety profile in advanced melanoma patients who progressed on anti–PD-1 therapy, with a 33.6% overall response rate and a 15.0% complete response rate. The median duration of response was 21.6 months, and most treatment-related adverse events were grade 1 or 2. A phase 3 trial, IGNYTE-3, is underway to further evaluate this combination.